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Abstract
Background: As a result of widespread chloroquine and sulphadoxine-pyrimethamine (SP) resistance, 90% of sub-
Saharan African countries had adopted policies of artemisinin-based combination therapy (ACT) for treatment of
uncomplicated malaria by 2007. In Malawi, cessation of chloroquine use was followed by the re-emergence of
chloroquine-susceptible malaria. It was expected that introduction of ACT would lead to a return in chloroquine
susceptibility throughout Africa, but this has not yet widely occurred. This observation suggests that there is
continuing use of ineffective anti-malarials in Africa and that persistent chloroquine-resistant malaria is due to
ongoing drug pressure despite national policy changes.
Methods: To estimate drug use on a national level, 2006-2007 Demographic Health Survey and Multiple Indicator
Cluster Survey data from 21 African countries were analysed. Resistance data were compiled by systematic review
of the published literature on the prevalence of the Plasmodium falciparum chloroquine resistance transporter
polymorphism at codon 76, which causes chloroquine resistance.
Results: Chloroquine was the most common anti-malarial used according to surveys from 14 of 21 countries
analysed, predominantly in West Africa. SP was most commonly reported in two of 21 countries. Among eight
countries with longitudinal molecular resistance data, the four countries where the highest proportion of children
treated for fever received chloroquine (Uganda, Burkina Faso, Guinea Bissau, and Mali) also showed no significant
declines in the prevalence of chloroquine-resistant infections. The three countries with low or decreasing
chloroquine use among children who reported fever treatment (Malawi, Kenya, and Tanzania) had statistically
significant declines in the prevalence of chloroquine resistance.
Conclusions: This study demonstrates that in 2006-2007, chloroquine and SP continued to be used at high rates
in many African countries. In countries reporting sustained chloroquine use, chloroquine-resistant malaria persists.
In contrast, a low level of estimated chloroquine use is associated with a declining prevalence of chloroquine
resistance.
Background
Chloroquine, an inexpensive, safe and once effective
anti-malarial, was a pillar of 20th century malaria eradi-
cation and control efforts. Until recently, the only widely
available alternative was sulphadoxine-pyrimethamine
(SP). These therapies have been compromised by the
spread of drug resistance, leading the World Health
Organization (WHO) to recommend and almost all
malaria endemic countries to implement policies endor-
sing the use of artemisinin-based combination therapy
(ACT) as the primary treatment regimen for uncompli-
cated malaria. However, the 2008 World Malaria Report
showed that only 3% of children with suspected malaria
were treated with ACT [1], suggesting that many chil-
dren were still receiving chloroquine and SP for malaria
treatment. Continued use of these therapies contributes
to the ongoing high malaria morbidity and mortality in
sub-Saharan Africa and exerts selective pressure to
maintain high rates of drug resistance in the malaria
parasite population.
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In the last decade, it was demonstrated that chloro-
quine-susceptible malaria parasites can regain predomi-
nance over chloroquine-resistant parasites after the
withdrawal of drug pressure. In 1993, Malawi was the
first African country to discontinue the policy of chloro-
quine use for uncomplicated malaria treatment. At that
time, treatment failure rates were above 50% [2]. The
presence of threonine at position 76 of the Plasmodium
falciparum chloroquine resistance transporter gene
(pfcrt), the molecular marker for chloroquine resistance
[3], was present in approximately 85% of infections [4].
After 2001, the resistant pfcrt genotype was no longer
detectable, suggesting that chloroquine-susceptible
malaria had regained predominance in Malawi. In 2005,
the return of treatment efficacy in Malawi was con-
firmed in a clinical trial that demonstrated that chloro-
quine had 99% efficacy for the treatment of
uncomplicated malaria [5]. A decline in the chloro-
quine-resistant form of pfcrt has also been recently been
documented in Kilifi, Kenya [6], where the policy of
chloroquine was changed to SP in 1999 [7]. In Niger,
where chloroquine use was not officially stopped until
2005, parasites carrying chloroquine-resistant genotypes
have been increasing in recent years [8]. Other than
these examples, little is known about longitudinal pat-
terns of chloroquine resistance in African countries.
Moreover, the relationship between objective measure-
ments of drug pressure and trends in chloroquine sus-
ceptibility has not been described. This study tests the
hypothesis that changes in the prevalence of chloro-
quine-resistant malaria will reflect changes in reported
chloroquine use on a national level.
Methods
Drug use survey design and selection criteria
Drug use within each country was estimated based on
publicly available data from Demographic Health Sur-
veys (DHS) and Multiple Indicator Cluster Surveys
(MICS). The DHS and MICS are nationally adminis-
tered household surveys, which use two-stage cluster
sampling to assess health indicators [9,10]. Within
selected enumeration areas, households are randomly
chosen for inclusion in the survey. All women in these
households, ages 15 to 49 years, are eligible for partici-
pation. Child health modules are completed for each
child of the respondent born within the last five years.
Most surveys conducted in the last ten years assess the
type of treatment used for children reporting fever or
convulsions within the preceding two weeks.
Survey data were obtained through MeasureDHS and
United Nations Children’s Fund (UNICEF) for all sub-
Saharan African countries that conducted DHS or MICS
surveys from 2006–2007, which were the most recent
data available in December 2009. Countries that were
not malaria-endemic were excluded. Results from 2006-
2007 surveys, as well as any data from any earlier DHS
or MICS surveys conducted in that country, were
included in the analysis.
Drug resistance data identification and collection
Trends in chloroquine resistance were assessed by using
the reported prevalence of the chloroquine-resistance
marker pfcrt 76T in countries that had household chlor-
oquine use data available for at least two time points. A
systematic literature review was performed in PubMed
using the search terms [country name + (pfcrt OR chlor-
oquine resistance)] for all eligible countries. Publication
dates were restricted to January 2001 through October
2009.
Although the presence of pfcrt 76T does not correlate
perfectly with treatment failure in populations [3,11], it
is an indicator of the parasite’s intrinsic resistance to
chloroquine [12]. Therefore, prevalence of pfcrt 76T
measured at each site is used as a surrogate for the level
of chloroquine-resistant parasites for the purposes of
this study.
Studies with data reporting the distribution of pfcrt 76
polymorphisms from population surveys or day zero
samples from clinical trials were reviewed. Only infec-
tions reported as ‘pure’ pfcrt 76T were included to
improve comparability of estimates across studies. In
sub-Saharan Africa, many infections are mixed, but pre-
cise assessment of allelic frequency within a single
human host has not been conducted in most field stu-
dies. Additionally, genotyping methods vary in sensitivity
of detecting minor alleles [13] and consequently in the
ability to detect mixed infections. As a result, infections
designated as ‘mixed’ may contain both sensitive and
resistant pfcrt 76 alleles at proportions that vary greatly
across samples and studies. In contrast, samples desig-
nated as ‘pure’ pfcrt 76T likely represent predominantly
resistant infections that are more comparable in allelic
composition. Countries with chloroquine-resistance pre-
valence data from at least four time points were
included in the final analysis. For each study that met
the criteria listed above, the prevalence of infection with
exclusively chloroquine-resistant parasites was recorded
along with additional information on inclusion criteria,
genotyping methods and the study site. Authors were
contacted for all studies in which these data could not
be collected directly from the publication.
Statistical analysis
Data were analysed in STATA 9.1 (StataCorp, College
Station, Texas). For DHS and MICS data, treatment of
an illness was defined as the reported use of anti-malar-
ials, antibiotics, antipyretics, other symptomatic thera-
pies, and traditional medicine treatments. The
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proportion with 95% confidence intervals of children
who reported treatment among all children who had
fever or convulsions was calculated, and the proportion
of children who reported anti-malarial use of all chil-
dren who had fever or convulsions was calculated. Pro-
portions and 95% confidence intervals of children who
received chloroquine, SP, amodiaquine, ACT, and qui-
nine among the total number of children who had
received treatment for fever or convulsions were calcu-
lated. Variability in survey design did not allow the reli-
able calculation of the proportion of children who took
chloroquine, SP, amodiaquine, ACT, and quinine among
those who received anti-malarials.
Multivariate logistic regression of chloroquine-resis-
tant infection prevalence over time was performed for
each country, controlling for study site as a proxy for
the effects of geographical variation and study partici-
pant characteristics (genotyping method, cross-sectional
survey versus clinical trial, age range, and symptomatic
status). The regression coefficient for time (in years) was
used to model the temporal trend in chloroquine resis-
tance prevalence. The correlation between 2006-2007
estimated chloroquine use and most recent reported
prevalence of pfcrt 76T was calculated.
Results
Twenty-three countries met the inclusion criteria for the
drug use analysis. Twenty-one of these had data, which
was publically available from the 2006–2007 survey. See
Additional File 1: Supplemental Table 1 for a list of the
surveys used in the analysis. The proportions of children
with fever or convulsions who reported treatment with
an anti-malarial are illustrated in Figure 1. The Gambia,
Uganda, and Ghana had the highest proportion of chil-
dren receiving anti-malarials for the treatment of fever
or convulsions with 63%, 62% and 61%, respectively.
The proportions of children who received chloroquine,
SP and ACT among all children who were treated for
fever or convulsions are shown in Figure 2. Chloroquine
was the most common anti-malarial reported in 14 of 21
countries and reported use was particularly high in West
Africa. SP was the most commonly reported anti-malarial
used in two East African countries, Zambia and Malawi.
Reported SP use was low throughout West Africa.
Use of anti-malarials other than SP and chloroquine
was reported as relatively low across all countries ana-
lysed. Amodiaquine was the most common treatment
only in Angola. More than ten percent of children also
reported amodiaquine use in Tanzania, Ghana, and
Cameroon. Among countries with 2006–2007 data, Tan-
zania was the only one in which the most commonly
reported anti-malarial was an ACT, with 22% of chil-
dren treated for fever reporting use of a “combination
with artemisinins.”
Nineteen of the 23 countries had two or more years
of DHS and MICS survey data available allowing for
estimation of chloroquine use trends and were, there-
fore, eligible for inclusion in the analysis of the effect
of reported drug use on chloroquine resistance.
Among these, eight had published chloroquine resis-
tance data covering at least four years. Molecular data
spanned a range of four to 16 years per country. The
studies from these countries evaluated in molecular
marker analysis are described in additional file 2: Sup-
plemental Table 2 [3-6,8,14-48]. All data from one
study [49] and data from three sites in a second study
[37] were excluded, both from Burkina Faso, because
pure and mixed infections could not be differentiated.
Reported chloroquine use and logistic regression mod-
elling of chloroquine resistance prevalence over time
are summarized in Figure 3.
Uganda, Burkina Faso and Guinea-Bissau reported >40%
chloroquine use sustained across surveys, from the early
to the mid-2000’s. These countries did not have signifi-
cant declines in the level of chloroquine resistance over
time (Figure 3). However, the prevalence of chloroquine
resistance among these three countries varied consider-
ably. In Uganda, chloroquine resistance appears fixed in
the population, with the prevalence of purely resistant
infections at nearly 100% over a ten-year period. Chloro-
quine resistance in Burkina Faso increased slightly, with
predicted purely resistant infection prevalence ranging
from approximately 50-70%. In Guinea Bissau resistance
prevalence was approximately 20%, the lowest of the
three countries.
Niger was the only country among the eight countries
analysed to report an increase in chloroquine use over
the last decade. Based on very limited molecular surveys,
the prevalence of chloroquine resistance rose, as well.
The few reports of chloroquine resistance prevalence
spanned a short time period, from 2003–2006.
Malawi, Kenya, Tanzania and Mali all reported low or
declining chloroquine use during the study period.
Reported chloroquine use was low (< 5%) in all years
surveyed in Malawi and Tanzania, although chloroquine
use was ubiquitous prior to the period included in this
analysis. Estimated use in Kenya declined from nearly
50% to 4% between 2000 and 2003. Malawi, Tanzania
and Kenya each exhibited a significant decline in the
prevalence chloroquine resistance over time (Figure 3).
The decline in Kenya (time coefficient -0.12), although
statistically significant, is occurring at a slower rate than
in Malawi or Tanzania (time coefficient -0.51 and -0.55,
respectively). A decrease in but not elimination of chlor-
oquine use between 2000 and 2006 (52% to 29%) was
reported from Mali. From 1996 to 2004 there appears to
have been a slight rise in the level of resistance in the
sites sampled. Evidence of the distribution of drug
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resistance after 2006 was not available from Mali when
the decline in chloroquine use was reported.
There was no correlation between most recent
reported chloroquine use and pfcrt 76T prevalence at
that time point by country (slope = 0.08; 95% confi-
dence interval = -1.21 - 1.37; r = 0.06).
Discussion
There is a renewed commitment to pursue malaria era-
dication. Access to effective therapy is an essential com-
ponent of this effort. With emerging concerns of
artemisinin resistance in Asia [50,51] and the possibility
that drugs previously compromised by resistance can
regain efficacy, it is important that we elucidate the
effect of drug use on the dynamics of anti-malarial resis-
tance. A review of the most recent data on chloroquine
and SP use patterns in Africa and the first multi-country
analysis of the relationship between anti-malarial drug
use and the prevalence of resistant infections is pre-
sented here. This review of DHS and MICS survey data
reveals that, as of 2006–2007, the estimated proportion
of chloroquine and SP use in many African countries
remained high. Furthermore, the descriptive compari-
sons of reported chloroquine use to patterns in pfcrt
supports the hypothesis that in Africa widespread chlor-
oquine use is associated with the persistence of chloro-
quine-resistant parasites, while a decrease chloroquine
use is associated with a decline in the resistance.
Limitations of the DHS and MICS data include inac-
curacies inherent to information derived from surveys
and from selection bias, arising from non-random fac-
tors influencing when and where surveys are conducted
and successfully completed. Molecular marker data may
also be affected by selection bias introduced in choosing
study sites and by publication bias. More dense spatial
representation may better estimate prevalence on a
national scale, particularly because local variation in the
prevalence of chloroquine resistance within the same
country has been documented [33,52]. Finally, there are
varying strategies to estimate haplotype frequencies
within parasites causing human infection [13]. The
selected method was limited to reviewing previously col-
lected data without precise measurements of allelic fre-
quency. Despite these limitations, the analysis presented
Figure 1 Anti-malarial use in Africa for the treatment of fever or convulsions. Map of African malaria endemic countries showing the
proportion of children under age 5 with fever or convulsions within the last 2 weeks that reported the use of anti-malarials.
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here uses data derived from the most comprehensive
sources available at this time.
National treatment policy versus reported drug use
Of the 21 countries evaluated for their anti-malarial use
in 2006-2007, only three reported highest use of the
regimen that was the national first line treatment policy
at the time. Among them, only Tanzania had adopted a
policy of ACT use and reported survey results that cor-
responded with this policy. Studies that evaluate the
prevalence of drug resistance may interpret their results
in the context of the treatment policy at the time of the
survey [52]. However, the findings presented here
demonstrate the shortcomings of such an assumption.
Because treatment practice may not be in accordance
with the official treatment policy, realistic estimates of
drug use should be included when characterizing drug
pressure.
Patterns in reported anti-malarial use
The estimated use of chloroquine and SP displays a
strong regional pattern, with high chloroquine use
reported in West Africa and more SP use reported in
East Africa. This may be attributed to several factors.
Resistance to chloroquine arose earlier and reached
higher levels in East Africa [53]. As a result, treatment
policies in East Africa tended to transition away from
chloroquine earlier than the rest of Africa, usually with
an interim policy utilizing SP. Higher levels of clini-
cally apparent chloroquine treatment failure over a
longer period of time in East Africa also may have
made providers and patients more receptive to the
recommended policy transition to non-chloroquine
regimens. Although West Africa saw a rise in chloro-
quine resistance later than other areas of the conti-
nent, several studies including some reviewed in this
analysis demonstrate that chloroquine-resistant para-
sites have come to dominate many of these parasite
populations, as well [43,52,55-60].
Chloroquine use and drug resistance
Longitudinal trends in pfcrt 76T prevalence in Malawi,
Kenya and Tanzania, the three countries with histori-
cally high but recently low chloroquine use, support the
hypothesis that a decline in chloroquine resistance
occurs with the withdrawal of drug pressure. In Malawi,
chloroquine use was negligible by 2000 and chloroquine
resistance had disappeared by 2003. Tanzania appears to
follow a similar pattern, with a significant downward
trend in the prevalence of pfcrt 76T. Chloroquine resis-
tance is declining in Kenya as well, as previously
demonstrated in Kilifi [6], although more gradually than
in Tanzania and Malawi. The slower rate may be a
result of amodiaquine use [61], which was reported to
have been taken by 9.6% of sampled children treated for
fever in the 2003 DHS survey in Kenya [62]. However,
East Africa
Malawia 13 0.8 (0.6,1.1) 24.9 (23.8,25.9) 0.2 (0.1,0.3)
Somaliaa 1 37.0 (29.9,44.0) 14.7 (9.5,19.8) 5.4 (2.1,8.7)
Tanzaniad,‡ 6 0.5 (0.1,0.9) 6.5 (5.0,7.9) 22.2 (19.7,24.7)
Ugandac 0 45.5 (43.7,47.3) 21.4 (19.9,22.9) 3.5 (2.8,4.2)
Zambiad 5 0.6 (0.1,1.1) 28.4 (25.4,31.4) 13.4 (11.1,15.6)
Zimbabwec 2 51.9 (42.2,61.6) 0.9 (-0.9,2.8) - (-,-)
Central Africa
Angolad,‡ * 14.7 (9.7,19.7) 0.5 (-0.5,1.5) 4.1 (1.3,6.8)
Cameroona,†,‡ 4 8.8 (7.0,10.5) 1.1 (0.5,1.8) 3.0 (2.0,4.1)
DRCd 6 8.5 (7.3,9.7) 3.1 (2.3,3.9) 1.3 (0.8,1.9)
West Africa
Beninc 2 51.6 (50.0,53.1) 0.5 (0.2,0.7) 0.4 (0.2,0.6)
Burkina Fasoa * 56.8 (53.3,60.3) 0.5 (0.0,1.0) - (-,-)
Cote d'Ivoirea 3 38.9 (36.6,41.2) 2.0 (1.4,2.7) 2.9 (2.1,3.7)
Gambiaa 1 66.9 (62.6,71.2) 14.8 (11.6,18.1) 0.2 (-0.2,0.6)
Ghanaa 2 47.4 (43.8,50.9) 0.7 (0.1,1.2) 3.6 (2.2,4.9)
Guinea-Bissaua -2 64.9 (60.7,69.1) 3.6 (1.9,5.2) 2.6 (1.2,3.9)
Liberiad 3 49.1 (46.4,51.7) 4.4 (3.3,5.4) 9.4 (7.9,11.0)
Malic 4 28.9 (26.7,31.1) 3.4 (2.5,4.2) 0.2 (0.0,0.5)
Mauritaniab,† * 11.7 (9.4,14.0) 6.0 (4.3,7.7) 2.0 (1.0,3.1)
Nigerc 1 44.2 (41.6,46.7) 1.0  (0.5,1.5) - (-,-)
Senegalc 3 10.6 (8.9,12.4) 0.4 (0.1,0.8) 9.7 (8.1,11.4)
Togoa * 36.7 (33.1,40.3) 3.8  (2.4,5.3) 1.6 (0.7,2.6)
Yrs since 
sanctioned CQ use 
at time of survey
Percentage of all children treated for fever (95% confidence interval)
CQ SP ACT
Figure 2 Drug use data from 21 DHS and MICS household surveys, 2006–2007. a MICS 2006. b MICS 2007. c DHS 2006. d DHS 2007. †
>15% reporting quinine use. ‡ >15% reporting amodiaquine use. *Year of official policy change could not be confirmed.
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reported chloroquine use was also high in Kenya until at
least 2000, and the full effect of decreased chloroquine
use may not become evident for several years.
The four countries with sustained reported chloro-
quine use at moderate to high levels exhibited no
change or even slight increases in the prevalence of
pfcrt 76T. In Uganda, almost all infections were chloro-
quine-resistant, while in Burkina Faso and Mali half to
three quarters of the infections were chloroquine-resis-
tant. Prevalence of pfcrt 76T in Guinea Bissau was lower
than Uganda, Burkina Faso and Mali, but remained
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Figure 3 Longitudinal chloroquine use and chloroquine resistance trends. Bars indicate the proportion of children who had fever or
convulsions in the preceding two weeks who reported chloroquine use. Observed (dots) and predicted prevalence using regression modelling
(trendlines) of pfcrt 76T are displayed with the coefficient for time in years with p-value (b) for the country regression model in the upper right
hand corner of each graph.
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prevalence is unclear. Seasonality of the transmission
patterns in East versus West Africa could be a contri-
buting factor. In Uganda, malaria transmission is peren-
nial, characterized by year-round infections with peaks
during rainy seasons. As a result, treatment occurs
throughout the year, subjecting parasites to constant
selective pressure. In contrast, the more seasonal trans-
mission of the West African Sahel, including Burkina
Faso and Mali, may lead to prolonged periods of lower
anti-malarial use. The prevalence of chloroquine-resis-
tant alleles was shown to increase over the transmission
season and decrease between seasons in a study con-
ducted in The Gambia, suggesting that the transient
decrease in drug pressure is enough to allow for the
resurgence of susceptible parasites [63].
Differences in access to anti-malarial treatment are
also a possible contributor to the varying levels of pfcrt
76T in Guinea-Bissau, Burkina Faso, Mali, and Uganda.
If a large proportion of children with fever go untreated,
even when chloroquine is the most commonly used
anti-malarial, a large proportion of the parasite popula-
tion is not subjected to chloroquine selective pressure.
This may contribute to the high level of resistant para-
sites in Uganda, which has among the highest anti-
malarial coverage for the treatment of fever, likely due
to the use of home based therapies. However, this does
not adequately address the differences in pfcrt 76T levels
seen in West Africa, where Guinea Bissau, Mali, and
Burkina Faso had similar anti-malarial coverage for feb-
rile and convulsive children, ranging from 33-46%. A
wide range of factors including environmental condi-
tions, access to medication, host immunity, duration of
drug pressure and others likely contribute to the differ-
ing baseline levels of resistant alleles.
This study demonstrates that as of 2006-2007,
reported anti-malarial use did not reflect national policy
in several countries. The analysis does suggest that in
Africa, changes in prevalence of pfcrt 76T are related to
estimates of drug use. This relationship raises the possi-
bility that the level of resistance could be used as an
indicator of continuing drug use. However, the lack of
correlation between the most recent point estimates of
drug use and prevalence of pfcrt 76T indicates that
chloroquine resistance is not always related to current
levels of drug pressure. This point is exemplified by
Kenya, where reported use in 2003 was 4% but pfcrt
76T prevalence was 80% as of 2007. Rather, it appears
that chloroquine resistance declines only under sus-
tained conditions of very low or near-absent use, as
demonstrated by the cases of Malawi and Tanzania. The
level of resistance maintained by high drug pressure
may vary by country and epidemiological situation, as
seen by comparing Uganda and Guinea-Bissau. Addi-
tionally, while pfcrt 76T has declined in some African
countries, the resistant genotype remains fixed in some
regions of Southeast Asia and Latin America after dec-
ades of little to no chloroquine use for P. falciparum
infection [64-66]. This may be due to reduced parasite
diversity in low compared to high transmission settings,
leading to decreased opportunities for recombination
and the fixation of alleles in the population. As ACT
uptake increases and transmission decreases in Africa, it
will be informative to examine the dynamics of chloro-
quine susceptibility within the parasite populations in
different settings. The return of chloroquine sensitivity
in Malawi has been attributed to the re-expansion of
sensitive parasites that survived in the population
despite drug pressure rather than reversion of resistant
parasites [67]. The return of chloroquine sensitivity to
other countries is likely to depend on the availability of
circulating chloroquine-susceptible parasites to out-
compete the resistant population in the absence of drug
pressure.
The wealth of standardized information collected in
DHS and MICS surveys along with published informa-
tion on the prevalence of chloroquine resistance has
allowed us to take a step toward understanding the rela-
tionship between estimates of drug pressure and the
dynamics of drug-resistant malaria. As an increasing
amount of data on molecular markers, in vitro and clini-
cal estimates of resistance are made available via initia-
tives such as the WorldWide Antimalarial Resistance
Network (WWARN), our ability to characterize the level
of resistance in different geographic areas will become
more comprehensive and precise. This knowledge will
inform targeted, rational approaches to the study of
drug resistance and the design of more efficient and
cost effective programs to curb resistance.
Conclusions
The results presented here suggest that the evolutionary
effects of anti-malarial treatment pressure on malaria
parasite populations can be reversed. As ACT use
increases throughout Africa, it is possible that chloro-
quine may be used in the future with appropriate part-
ner drugs and possibly limited to targeted populations.
Moreover, as resistance to artemisinins continues to
evolve in Southeast Asia, success in preventing the
spread of anti-malarial resistance will depend on the
ability to anticipate its emergence and spread under a
variety environmental and policy scenarios.
Additional material
Additional File 1: Supplemental Table 1 Surveys used in analysis of
the treatment of fever or convulsions in children under 5 years of
age. *Sample sizes taken from DHS and MICS child datasets, which
include all children from sampled households under the age of 5 years.
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Additional File 2: Supplemental Table 2: Plasmodium falciparum
pfcrt 76T prevalence studies used in chloroquine resistance
prevalence analysis. UK = unknown. m = months. y = years. UC =
uncomplicated malaria. AS = asymptomatic infection. SM = severe
malaria. SI = symptomatic infection.
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